Wells Fargo sets LeMaitre stock at Equal Weight, $95 target

Published 13/02/2025, 11:52
Wells Fargo sets LeMaitre stock at Equal Weight, $95 target

On Thursday, Wells Fargo (NYSE:WFC) initiated coverage on LeMaitre Vascular (NASDAQ:LMAT) with an Equal Weight rating and established a price target of $95.00. According to InvestingPro data, the company maintains a "GREAT" financial health score and has demonstrated strong revenue growth of 14.8% over the last twelve months. LeMaitre Vascular is recognized as a prominent entity in various specialized open vascular surgery markets, notably contributing to arteriovenous (AV) access for dialysis, which accounts for approximately 22% of its revenue, and carotid endarterectomy (CEA), making up about 15% of revenue.

Wells Fargo’s assessment indicates that LeMaitre’s end markets are experiencing flat to low-single-digit volume growth. The company’s strategy for organic growth includes hiring additional sales representatives, extending product approvals to new regions, enhancing direct sales outside the United States, improving cross-selling opportunities, and implementing price increases. Notable strengths include its 14-year track record of consecutive dividend increases and strong liquidity position, with a current ratio of 7.74.

LeMaitre Vascular’s stock is currently trading at around 45 times Wells Fargo’s estimated earnings per share (EPS) for 2025. This valuation surpasses the company’s historical average of approximately 38 times EPS and is notably higher, by roughly 100%, compared to its competitors, as opposed to the average premium of about 40% observed from 2018 to 2024.

Wells Fargo suggests that the premium valuation of LeMaitre’s shares is influenced by two main factors: investor confidence in the company’s ability to manage pricing effectively and the potential for mergers and acquisitions to exceed the market’s expectations. However, at the current valuation, Wells Fargo believes that the stock price has already integrated an optimistic perspective regarding the company’s potential for pricing and volume growth for the year 2025 and beyond.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.